Autoimmune Inc.

The Brigham and Women's Hospital, Inc.

Leland Stanford Junior University

The United States of America As Represented by the Department of Health

Dana-farber-cancer Institute Inc.

The United States Government As Represented by the Department of Veterans Affairs

David A Hafler

Howard L Weiner

Zhengyi Zhang

David E Trentham

George S Eisenbarth

Charles B Carpenter

Mohamed Sayegh

Zhengi Zhang

Ariel Miller

Ahmad Al-Sabbagh

George Eisenberth

Jack L Strominger

Lawrence Steinman

Vijay K Kuchroo

Kai W Wucherpfennig

David E Anderson

William H Robinson

Robert B Nussenblatt

Alan G Palestine

Mohammed Oukka

Kevin C O'Connor

Katherine McLaughlin

Estelle Bettelli

Brian Wilson

Sally C Kent

The embodiments provide for the modulation of both the differentiation and activity of human T17 cells. More specifically, human T17 cell differentiation can modulated by TGF-&#x3b2; and IL-21, and their agonists and antagonists. Function of T17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of T17 cells. More specifically, human T17 cells specifically upregulate BLT1 and podoplanin.

Selective differentiation, identification, and modulation of human TH17 cells

Methods and compositions for diagnosing and treating autoimmune disease, e.g., acute disseminated encephalomyelitis (ADEM), are described.

Diagnosis of autoimmune disease

Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.

Method of treating or preventing Type 1 diabetes by oral administration of insulin

The present invention is directed to methods that can be used for diagnosing whether an individual either has, or is likely to develop, an autoimmune disease. The methods are based upon determining the level of CD4.sup.- CD8.sup.- V.alpha.24J.alpha.Q.sup.+ T cells present in the individual being tested or the pattern of cytokine secretion evidenced by these cells. In addition, the invention is directed to a therapeutic method for treating or preventing autoimmune disease which is based upon the specific expansion of the CD4.sup.- CD8.sup.- V.alpha.24J.alpha.Q.sup.+ T cell population.

Diagnostic and therapeutic methods based upon V.alpha.24J.alpha.QT cells

Peptides containing regions of myelin basic protein found in the 86-102 and 143-168 sequences that are immunodominant in humans suffering from multiple sclerosis.

Peptide fragments of myelin basic protein

Peptides containing immunodominant epitopes of myelin basic protein that are recognized by groups of T-cells from remitting-relapsing multiple sclerosis patients.

Peptides derived from immunodominant epitopes of myelin basic protein

Peptides are administered to individuals suffering from multiple sclerosis. The peptides contain immunodominant epitopes of myelin basic protein that are recognized by T-cells from relapsing-remitting multiple sclerosis patients, and that are contained in the 84-102 and 143-168 regions of human MBP.

Suppression of T-cell proliferation using peptide fragments of myelin

The present invention provides a method of treating or preventing the clinical manifestation of an autoimmune disease having the symptoms of uveoretinitis in a mammal in need of such treatment comprising orally administering to said mammal an effective amount of an autoantigen, e.g., S antigen (S-Ag), and/or biologically active fragments, or analogs thereof specific for uveoretinitis. Also provided is a pharmaceutical formulation useful for treating or preventing uveoretinitis in mammals comprising an effective amount of one or more of the foregoing autoantigen, fragments or analogs.

Method of treating or preventing autoimmune uveoretinitis in mammals

The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Treatment of immune diseases by oral administration of autoantigens

The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Treatment of multiple sclerosis by oral administration of autoantigens

Method of treating or preventing type 1 diabetes by oral administration

Peptides ate provided that are related to immunodominant regions of human MBP.

Pharmaceutical dosage form for treatment of multiple sclerosis

A method for suppressing autoimmune response in an afflicted joint in a human. The method involves oral administration of between about 5 and 25 .mu.g per day of type II collagen.

Method of treating rheumatoid arthritis with low dose type II collagen

The invention is directed to a method of treating multiple sclerosis in animals, including humans, by the oral administration of bovine myelin.

Growing community of inventors

West Newton, MA, United States of America

David A Hafler